Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIE phase 2 trial of lenvatinib plus ifosfamide/etoposide versus ifosfamide/etoposide in relapsed or refractory osteosarcoma
MOH_2020-03-19_008781Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in osteosarcoma (OS) comparing Lenvatinib in combination with ifosfamide and etoposide with Ifosfamide and etoposide (2 arms). Primary endpoint: Progression-free survival at 4 months. Started Feb 2020; status: completed.
02
Drugs
lenvatinibifosfamideetoposide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on MOH_2020-03-19_008781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-19_008781.